Onco Actu du 18 mai 2015

Voir aussi le "Spécial ASCO" du jour

	1. Biologie
Single Cells Analyzed at Unprecedented Scale [MIT Technology Review] Regev says she has been working with the new methods to classify cells in mouse retinas and human brain tumors, and she is finding cell types never seen before. “We don’t really know what we’re made of,” she says.
	3.1 Tabac
Financial incentives could help smokers quit says US study [Cancer Research UK] Chris Woodhall, Cancer Research UK’s senior tobacco control officer, welcomed the findings, but cautioned that they would need to be replicated among UK smokers.
Keeping Our Kids Safe From E-cigarettes [CANCER RESEARCH Catalyst] We are encouraged by the recognition by many members of Congress that we must protect youth from these products.
Want to quit smoking? Penalties more effective than rewards, new study finds [The Guardian] More people signed up to program that offered $800 cash than one that threatened them with losing a $150 deposit – but fewer gave up.
Incentive Programs to Urge Smokers to Quit: Lessons from Behavioral Science [Now@NEJM] These results have exciting implications for how to help smokers quit. First, as behavioral scientists would have predicted, the risk of losing money is better for inspiring cessation behavior than the potential to make money.
To make smokers healthy, it helps to make them wealthy, study finds [LA Times] The Penn researchers concluded that simply paying smokers to quit was the most “effective” way to go because people were so much more willing to give it a try.
	3.3 Prévention - Vaccins
HPV Vaccine Compliance [Science-Based Medicine] The only real barrier to full implementation is ideology – distrust of science, medicine, government, or corporations, irrational worship of the concept of “natural”, belief in magical medical nonsense, or the misguided belief that preventive measures promotes immoral behavior.
	4.1 Dép., diag. & prono. - Prostate
Oncotype DX ® Prostate Cancer Test Improves Risk Assessment for One in Four Men and Reduces Overall Healthcare Costs [Genomic Health] Data Presented at American Urological Association Annual Meeting Underscore Test's Value to Physicians, Patients and U.S. Healthcare System.
Myriad Validates Active Surveillance Threshold With Prolaris(R) for Men With Prostate Cancer [Myriad] In the validation data featured at AUA, the pre-defined AS threshold was evaluated in 765 conservatively managed men, and the clinical endpoint was 10-year risk of prostate cancer mortality.
	4.10 Dép., diag. & prono. - Poumon
Veracyte lung cancer test could help avoid some risky biopsies [Reuters] The company's Percepta Bronchial Genomic Classifier takes cell samples from the windpipe of smokers during a bronchoscopy procedure and analyzes 23 genes for their reaction to exposure to cigarette toxins.
	4.2 Dép., diag. & prono. - Génome
Mary-Claire King on Inherited Breast/Ovarian Cancer [MassGenomics] It is a rare but delightful opportunity to learn about something from an acknowledged world expert. Such was the case last month when I heard Mary-Claire King give the Stanley J. Korsmeyer Memorial lecture, hands-down one of the best talks I’ve ever heard. She was a wonderful public speaker: funny, charming, and straight-shooting.
Genomics-Enabled Learning Health Care Systems: Gathering and Using Genomic Information to Improve Patient Care and Research: Workshop Summary [The National Academies Press] The workshop examined how a variety of systems are capturing and making use of genomic data to generate knowledge for advancing health care in the 21st century. It also sought to evaluate the challenges, opportunities, and best practices for capturing or using genomic information in knowledge-generating health care systems.
How DNA sequencing is transforming the hunt for new drugs [Reuters] "All of a sudden, it all opened up," as companies recognize the potential for drugs targeting genetic glitches, Dr. Eric Topol, a genomics expert at the Scripps Translational Science Institute. "It's starting to really become a new preferred model for drug development."
	4.9 Dép., diag. & prono. - Sein
Breast Cancer Screening: Let Evidence Trump Fear [Health Affairs] As a nation, we’ve invested billions in research to improve our ability to prevent, screen for, diagnose and treat breast cancer. Let’s use it to better inform patients and their doctors and protect patients from unnecessary harm.
	5. Traitements
Refractory Metastatic Colon Cancer [Now@NEJM] TAS-102, a combination of trifluridine and tipiracil in which tipiracil interferes with the deactivation of trifluridine, improved overall and progression-free survival in patients whose disease had progressed after treatment with fluorouracil-containing drug combinations.
Scientists identify a new strategy to kill cancer cells [The Institute of Cancer Research] They found that by using drugs to block a molecule called WEE1 – which keeps cell division under control until DNA has been properly checked for errors – they could force cancer cells to make so many mistakes in their genetic code that they could no longer survive.
New drug combination extends survival of patients with metastatic colorectal cancer [Dana-Farber Cancer Institute] A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial.
Protein FGL2 May Have Potential as Therapy Target for Brain Cancer [MD Anderson Cancer Center] The study, using mouse models, data from The Cancer Genome Atlas (TCGA) and human tumor samples, found that FGL2 increased tumor growth in mice by enhancing immune checkpoint gene expression. The research team neutralized the protein by using an anti-FGL2 antibody.
	5.12 Immunothérapies
Advancing Immunotherapy for All Cancers [Cancer Research Institute Blog] Entitled “Translating Science into Survival,” the meeting will feature more than 60 talks by acknowledged leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy.
The Science of PD-1 and Immunotherapy [Dana-Farber Cancer Institute] This is a story about the velocity of an idea – a discovery whose potential to improve cancer treatment practically leapt from the test tube.
	5.2 Pharma
One of Takeda's big cancer bets flops in a Phase III lymphoma trial [FierceBiotech] The failure follows a similar setback for orteronel, a once-promising prostate cancer treatment that Takeda ditched last year after it came up short in Phase III. The company's most advanced cancer treatment is now ixazomib, an oral treatment for blood cancers that Takeda hopes can succeed its blockbuster Velcade.
	5.2.1 Pharma - Partenariats
Sorrento Sells Cynviloq for $1.3B [GEN] “Data analysis suggests that Cynviloq meets the bioequivalence (BE) criteria for both total and unbound paclitaxel,” Sorrento said on May 4.
Soon-Shiong bets $90M on Sorrento's next-gen Abraxane with $1.2B on the line [FierceBiotech] Cynviloq is in the midst of a Phase III study in breast and lung cancers with the goal of demonstrating bioequivalence to Abraxane, which uses the protein albumin to deliver a targeted blast of paclitaxel and kill tumors.
	5.4 Traitements - Economie
Non-Tyrosine Kinase Inhibitors in Oncology, 2015-2025 [Report Buyer] Non-tyrosine kinase inhibitors have gradually gained attention in the last few years. Amongst the marketed drugs, Nexavar and Afinitor have already achieved blockbuster status.
	6. Lutte contre les cancers
In praise of academic cancer treatment studies [The Cancer Blog] As a patient working in cancer research for over ten years now, one thing has slowly become more and more apparent. The greatest patient benefit accrues from studies which are academically led. A bold statement which needs a bit of unpicking.
	6.10 Politiques
America Needs Bolder Science And The 21st Century Cures Act Should Empower It [Forbes] For the last four years, I have served on the Advisory Council of the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH). A disheartening discovery from that experience has been the bias for funding safe science – at the expense of bold science – that pervades publicly-funded research.
The 21st Century Cures Act Evolves and Moves into Mark-Up [FDA Law Blog] The final bill should come up for a vote on the floor of the full House of Representatives sometime in June.
The 21st Century Cures Act and Drug Company Promotion of Real-World Data [Health Affairs] The language in the Discussion Draft may continue to change as the bill works its way through the legislative process. Still, the proposal to date reflects a step in the right direction.
Election 2015: What does the result mean for cancer? [Cancer Research UK] Throughout the last parliament, the Conservatives championed the benefits of medical research and the life sciences and their potential to boost economic recovery. But there are big spending cuts that have to be made and, apart from three protected areas, the NHS, schools and international aid, all departments are vulnerable.
	6.11 Patients
'Death is hard. Living with cancer can be harder' – in pictures [The Guardian] Four men have turned to photography, in a pilot project funded by Prostate Cancer UK, to share their views and experience of living with the disease
A moment that changed me – my first chemotherapy session [The Guardian] I don’t want cancer to change my life. But the night after my first chemotherapy session, I swore to my fiance I wouldn’t go through it again.
What I’m really thinking: the mother with cancer [The Guardian] Since I was diagnosed with breast cancer last summer, I’ve had surgery, chemotherapy and radiotherapy, and my appearance has undergone a major overhaul. Now, most of you avoid my eye, don’t smile and rarely stop for a chat. None of you is oblivious (even though you appear to be), because my cancer diagnosis is known throughout the school.
	6.8 Communication
The Fault In Our Stars: When Celebrity Health Advice Conflicts With Our Science [Dr Len] When it comes to sending a message to the country and the world about who should be screened and when they should start screening, we should use the opportunity to educate and inform about what we know, not what we assume.
	6.9 Controverses
Doctors issue warning about overtreating patients [NHS Choices] They say overdiagnosis and overtreatment are driven by "a culture of 'more is better', where the onus on doctors is to 'do something' at each consultation".